Tectonic Therapeutic, Inc. (TECX)
| Market Cap | 539.44M +47.9% |
| Revenue (ttm) | n/a |
| Net Income | -83.49M |
| EPS | -4.46 |
| Shares Out | 18.85M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 217,990 |
| Open | 27.00 |
| Previous Close | 26.87 |
| Day's Range | 27.00 - 29.26 |
| 52-Week Range | 14.39 - 36.03 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 75.20 (+162.75%) |
| Earnings Date | May 7, 2026 |
About TECX
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company’s lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPC... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for TECX stock is "Strong Buy." The 12-month stock price target is $75.2, which is an increase of 162.75% from the latest price.
News
Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights
WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic” or the “Company”), a clinical stage biotechnology company focused on the discovery and developm...
Tectonic Therapeutic management to meet with Piper Sandler
Meeting to be held in Boston on April 29 hosted by Piper Sandler. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See
Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors
WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeu...
Tectonic Therapeutic initiated with a Buy at Stifel
Stifel initiated coverage of Tectonic Therapeutic (TECX) with a Buy rating and $75 price target The firm thinks the risk/reward ahead of the Phase 2 APEX data due in late
Tectonic Therapeutic Transcript: Leerink Global Healthcare Conference 2026
Two clinical programs are advancing: TX45, a long-acting relaxin for pulmonary hypertension, is differentiated by patient selection and dosing, with Phase II results expected in late 2026 or early 2027. TX2100, an anti-angiogenic agent for HHT, shows strong preclinical efficacy and safety, with Phase I data due this year. The proprietary platform supports ongoing pipeline innovation.
Tectonic Therapeutic Transcript: TD Cowen 46th Annual Health Care Conference
The session highlighted progress on two clinical programs targeting major unmet needs in pulmonary hypertension and hereditary hemorrhagic telangiectasia, with key data readouts expected in late 2024 and 2026/2027. Competitive insights and trial design refinements position the pipeline for significant impact.
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
WATERTOWN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeut...
Tectonic Therapeutic Transcript: KOL event
TX2100 is a first-in-class APJ antagonist targeting HHT, aiming to address a major unmet need with a differentiated, pathology-biased anti-angiogenic mechanism. Robust preclinical efficacy and safety data support ongoing clinical trials, with a focus on improving epistaxis and expanding to related disorders.
Tectonic Therapeutic chair Terry McGuire to retire, Francois Nader to succeed
Tectonic Therapeutic (TECX) announced it has appointed Francois Nader as an independent director to its board of directors, effective April 1, at which time he will also assume the role
Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board
WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeut...
Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026
WATERTOWN, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeut...
Tectonic Therapeutic price target lowered to $60 from $64 at Truist
Truist analyst Danielle Brill lowered the firm’s price target on Tectonic Therapeutic (TECX) to $60 from $64 and keeps a Buy rating on the shares. The firm updated its model,
Tectonic Therapeutic Transcript: Piper Sandler 37th Annual Healthcare Conference
APEX study enrollment is progressing as planned, now focusing on high PVR patients for greater efficacy. No safety concerns have emerged, and the trial is differentiated by its design and molecular construct. Financially, the company is well-funded through Q4 2028.
Tectonic Therapeutic reports Q3 EPS ($1.02), consensus ($1.05)
“Our team continued to advance our lead asset TX45 with the positive topline data from Part B of our Phase 1b study in patients with HFrEF. Following our recent presentation
Tectonic Therapeutic Inc trading resumes
16:35 EDT Tectonic Therapeutic (TECX) Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing st...
Tectonic Therapeutic Transcript: Study Result
A single dose of TX45 in PH-FrEF patients was well tolerated and produced significant, sustained improvements in key hemodynamic parameters, including wedge pressure, PVR, and cardiac output, with echo data supporting persistent benefits at day 29. These results support further clinical development, with the APEX phase II trial ongoing and top-line data expected in 2026.
Tectonic Therapeutic Inc trading halted, news pending
16:00 EDT Tectonic Therapeutic (TECX) Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-...
Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF
WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced positive topline results from the Phase 1b Part B acute hemodynamic clinical...
Tectonic Therapeutic Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
TX45, a long-acting relaxin mimetic, is advancing through clinical trials for heart failure and pulmonary hypertension, showing strong efficacy in early studies. The pipeline is expanding to new indications, with additional programs and key data readouts expected through 2026.
Tectonic Therapeutic Transcript: Cantor Global Healthcare Conference 2025
A differentiated relaxin program is advancing with strong phase 1B data in pulmonary hypertension and a focus on stable, well-managed patients. Upcoming data in reduced ejection fraction heart failure and a new program in hereditary hemorrhagic telangiectasia expand the pipeline.
Tectonic Therapeutic initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Tectonic Therapeutic (TECX) with an Outperform rating and $80 price target The firm likes the prospects of the company’s lead asset TX45 to address prevalent and
Tectonic pullback on Eli Lilly relaxin data ‘overdone,’ says Truist
Truist analyst Danielle Brill notes that shares of Tectonic Therapeutic (TECX) are off by greater than 30% following Eli Lilly’s (LLY) data presentation and publication from their failed study in
Tectonic Therapeutic to Participate in September Investor Conferences
WATERTOWN, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeut...
Tectonic Therapeutic initiated with a Buy at Truist
Truist initiated coverage of Tectonic Therapeutic (TECX) with a Buy rating and $64 price target Tectonic is advancing lead relaxin asset, TX45 for Group 2 pulmonary hypertension-heart failure with pre...
Tectonic Therapeutic files $400M mixed securities shelf
17:50 EDT Tectonic Therapeutic (TECX) files $400M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s bes...